---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-223262"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:22:23.460730+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KalVista closes $143.75M convertible notes offering; net proceeds ~$139M for EKTERLY

## Summary
- Issued $143.75M in 3.250% Convertible Senior Notes due 2031, including full exercise of $18.75M greenshoe.
- Net proceeds ~$139M after discounts and expenses; used for working capital and EKTERLY commercialization.
- Initial conversion rate 59.4919 shares/$1,000 (conversion price ~$16.81), 30% premium over $12.93 close.
- Notes are senior, unsecured, callable after Oct 5, 2028 if stock price meets 130% conversion price threshold.

## SEC filing metadata
- accession: 0001193125-25-223262
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/0001193125-25-223262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/d83242d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-223262
- JSON: https://secwatch.observer/filing/0001193125-25-223262.json
- Plain text: https://secwatch.observer/filing/0001193125-25-223262.txt

## Key facts
- Debt Financings
  KalVista Pharmaceuticals, Inc. incurred convertible notes of $143.75 million in aggregate principal amount with Initial Purchasers at 3.250% maturing due 2031.
  - Instrument: convertible notes
  - Principal: $143.75 million in aggregate principal amount
  - Counterparty: Initial Purchasers
  - Rate: 3.250%
  - Maturity: due 2031
  - Event: incurrence
  source text: On September 29, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) completed its previously announced sale of $143.75 million in aggregate principal amount of its 3.250% Convertible Senior Notes due 2031
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/0001193125-25-223262-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.